- AFIB Dashboard
-
Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Acutus Medical (AFIB) Financial statements
Company Profile
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|---|
Total Revenue | |||||
Cost of Revenue | |||||
Gross Profit | |||||
Gross Profit Margin (%) | |||||
R&D Expense | |||||
SG&A Expense | |||||
Total Operating Expenses | |||||
Operating Income or Loss | |||||
Operating Margin (%) | |||||
Interest Expense | |||||
Total Other Income/Expenses | |||||
Income Before Tax | |||||
Income Tax Expense | |||||
Income from Continuing Ops. | |||||
Net Income | |||||
Net Profit Margin (%) | |||||
Net Income Available to Common Shareholders | |||||
Basic EPS | |||||
Diluted EPS | |||||
Basic Average Shares | |||||
Diluted Average Shares |
Sep 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | ||||||||||||||||||
Cost of Revenue | ||||||||||||||||||
Gross Profit | ||||||||||||||||||
Gross Profit Margin (%) | ||||||||||||||||||
R&D Expense | ||||||||||||||||||
SG&A Expense | ||||||||||||||||||
Total Operating Expenses | ||||||||||||||||||
Operating Income or Loss | ||||||||||||||||||
Operating Margin (%) | ||||||||||||||||||
Interest Expense | ||||||||||||||||||
Total Other Income/Expenses | ||||||||||||||||||
Income Before Tax | ||||||||||||||||||
Income Tax Expense | ||||||||||||||||||
Income from Continuing Ops. | ||||||||||||||||||
Net Income | ||||||||||||||||||
Net Profit Margin (%) | ||||||||||||||||||
Net Income Available to Common Shareholders | ||||||||||||||||||
Basic EPS | ||||||||||||||||||
Diluted EPS | ||||||||||||||||||
Basic Average Shares | ||||||||||||||||||
Diluted Average Shares |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|---|
Current Assets | |||||
Cash & Cash Equivalents | |||||
Marketable Securities | |||||
Receivables | |||||
Inventories | |||||
Other Current Assets | |||||
Total Current Assets | |||||
Non-Current Assets | |||||
Marketable Securities | |||||
PPE Net | |||||
Intangibles inc. Goodwill | |||||
Other Non-Current Assets | |||||
Total Non-Current Assets | |||||
Total Assets | |||||
Current Liabilities | |||||
Accounts Payable | |||||
Deferred Revenues | |||||
Debt, Current | |||||
Accrued Liabilities | |||||
Other Current Liabilities | |||||
Total Current Liabilities | |||||
Non-Current Liabilities | |||||
Deferred Revenues | |||||
Debt, Non-Current | |||||
Other Non-Current Liabilities | |||||
Total Non-Current Liabilities | |||||
Total Liabilities | |||||
Shareholders' Equity | |||||
Common Stock | |||||
Additional Paid-In Capital | |||||
Retained Earnings | |||||
Other Shareholders' Equity | |||||
Total Shareholders' Equity | |||||
Total Liabilities & Shareholders' Equity |
Sep 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Current Assets | ||||||||||||||||||
Cash & Cash Equivalents | ||||||||||||||||||
Marketable Securities | ||||||||||||||||||
Receivables | ||||||||||||||||||
Inventories | ||||||||||||||||||
Other Current Assets | ||||||||||||||||||
Total Current Assets | ||||||||||||||||||
Non-Current Assets | ||||||||||||||||||
Marketable Securities | ||||||||||||||||||
PPE Net | ||||||||||||||||||
Intangibles inc. Goodwill | ||||||||||||||||||
Other Non-Current Assets | ||||||||||||||||||
Total Non-Current Assets | ||||||||||||||||||
Total Assets | ||||||||||||||||||
Current Liabilities | ||||||||||||||||||
Accounts Payable | ||||||||||||||||||
Deferred Revenues | ||||||||||||||||||
Debt, Current | ||||||||||||||||||
Accrued Liabilities | ||||||||||||||||||
Other Current Liabilities | ||||||||||||||||||
Total Current Liabilities | ||||||||||||||||||
Non-Current Liabilities | ||||||||||||||||||
Deferred Revenues | ||||||||||||||||||
Debt, Non-Current | ||||||||||||||||||
Other Non-Current Liabilities | ||||||||||||||||||
Total Non-Current Liabilities | ||||||||||||||||||
Total Liabilities | ||||||||||||||||||
Shareholders' Equity | ||||||||||||||||||
Common Stock | ||||||||||||||||||
Additional Paid-In Capital | ||||||||||||||||||
Retained Earnings | ||||||||||||||||||
Other Shareholders' Equity | ||||||||||||||||||
Total Shareholders' Equity | ||||||||||||||||||
Total Liabilities & Shareholders' Equity |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|---|
Cash Flows from Operating Activities | |||||
Net Income | |||||
Depreciation & Amortization | |||||
Deferred Income Taxes | |||||
Stock Based Compensation | |||||
Accounts Receivable | |||||
Inventory | |||||
Accounts Payable | |||||
Deferred Revenue | |||||
Other Non-Cash | |||||
Operating Cash Flow | |||||
Cash Flows from Investing Activities | |||||
PPE Investments | |||||
Net Acquisitions | |||||
Purchase of Investments | |||||
Sale of Investments | |||||
Other Investing Activity | |||||
Investing Cash Flow | |||||
Cash Flows from Financing Activities | |||||
Debt Issued | |||||
Proceeds from Debt Repayment | |||||
Debt Repayment | |||||
Proceeds from Sale of Equity | |||||
Equity Repurchased | |||||
Dividend Paid | |||||
Other Financing Activity | |||||
Financing Cash Flow | |||||
Cash Position | |||||
Beginning Cash Position | |||||
End Cash Position | |||||
Change in Cash | |||||
Free Cash Flow | |||||
Operating Cash Flow | |||||
Capital Expenditure | |||||
Free Cash Flow |
Sep 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flows from Operating Activities | ||||||||||||||||||
Net Income | ||||||||||||||||||
Depreciation & Amortization | ||||||||||||||||||
Deferred Income Taxes | ||||||||||||||||||
Stock Based Compensation | ||||||||||||||||||
Accounts Receivable | ||||||||||||||||||
Inventory | ||||||||||||||||||
Accounts Payable | ||||||||||||||||||
Deferred Revenue | ||||||||||||||||||
Other Non-Cash | ||||||||||||||||||
Operating Cash Flow | ||||||||||||||||||
Cash Flows from Investing Activities | ||||||||||||||||||
PPE Investments | ||||||||||||||||||
Net Acquisitions | ||||||||||||||||||
Purchase of Investments | ||||||||||||||||||
Sale of Investments | ||||||||||||||||||
Other Investing Activity | ||||||||||||||||||
Investing Cash Flow | ||||||||||||||||||
Cash Flows from Financing Activities | ||||||||||||||||||
Debt Issued | ||||||||||||||||||
Proceeds from Debt Repayment | ||||||||||||||||||
Debt Repayment | ||||||||||||||||||
Proceeds from Sale of Equity | ||||||||||||||||||
Equity Repurchased | ||||||||||||||||||
Dividend Paid | ||||||||||||||||||
Other Financing Activity | ||||||||||||||||||
Financing Cash Flow | ||||||||||||||||||
Cash Position | ||||||||||||||||||
Beginning Cash Position | ||||||||||||||||||
End Cash Position | ||||||||||||||||||
Change in Cash | ||||||||||||||||||
Free Cash Flow | ||||||||||||||||||
Operating Cash Flow | ||||||||||||||||||
Capital Expenditure | ||||||||||||||||||
Free Cash Flow |